We previously reported early results from a phase I first-in-human study showing that CD7-directed CAR T cells manufactured from T cells collected from allogeneic donors with retention of CD7 molecules in the endoplasmic reticulum could partially overcome these barriers to treat r/r T-ALL [16]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.